



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

SALZWEDEL *et al.*

Appl. No.: 10/766,528

Filed: January 29, 2004

For: **Inhibition of HIV-1 Replication
by Disruption of the Processing of
the Viral Capsid-Spacer Peptide 1
Protein**

Confirmation No.: 2237

Art Unit: 1648

Examiner: HUMPHREY, Louise Wang
Zhiying

Atty. Docket: 1900.0430002/JMC/HCC

**First Supplemental Information Disclosure Statement
Under 37 C.F.R. § 1.97(c)**

Mail Stop Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying IDS Forms, PTO/SB/08A and PTO/SB/08B, are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. This First Supplemental Information Disclosure Statement is a continuation of the Applicants' Information Disclosure Statement filed on August 19, 2004 in connection with the above-captioned application.

Copies of documents **NPL1** to **NPL18** are submitted. However, in accordance with 37 C.F.R. § 1.98(a)(2), a copy of the U.S. patent application publication, document **US1**, cited on the attached IDS Form, PTO/SB/08A, is not submitted. In addition, a copy of document **NPL19** is not provided in accordance with the U.S. Patent and Trademark Office OG notice of October 19, 2004, which states: "the requirement in 37 C.F.R. § 1.98(a)(2)(iii) for a legible copy of the specification, including the claims, and drawings of each cited pending U.S. patent application or portion of the application

Void date: 01/23/2007 SZEWDIE1
01/23/2007 SZEWDIE1 00000117-190036-10766528
02 FC:1806 100.00 OP

01/23/2007 SZEWDIE1 00000118 10766528

02 FC:1806

100.00 OP

01/23/2007 SZEWDIE1 00000117-190036-10766528

02 FC:1806

100.00 DA

which caused it to be listed) is sua sponte waived where the cited pending application is stored in the USPTO's IFW system."

The Examiner's attention is directed to the following co-pending U.S. Patent Application, which is directed to related technical subject matter:

U.S. National Phase Patent Application No. 11/597,431, Salzwedel *et al.*, international filing date of May 24, 2005; pending, listed as document **NPL19**.

The identification of this U.S. Patent Application is not to be construed as a waiver of secrecy as to that application now or upon issuance of the present application as a patent. The Examiner is respectfully requested to consider the cited application and the art cited therein during examination.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent

application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection, or Notice of Allowance, or an action that otherwise closes prosecution in the application. Attached is our PTO-2-38 Credit Card Payment Form in the amount of \$180.00 in payment of the fee under 37 C.F.R. § 1.17(p).

It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Helene C. Carlson
Agent for Applicants
Registration No. 47,473

Date: 1/22/07

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

632948v2



U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

(Use as many sheets as necessary)

Sheet	1	of	1
-------	---	----	---

Complete if Known

Application Number	10/766,528
Filing Date	January 29, 2004
First Named Inventor	SALZWEDEL, Karl
Art Unit	1648
Examiner Name	HUMPHREY, Louise Wang Zhiying
Attorney Docket Number	1900.0430002/JMC/HCC

U.S. PATENT DOCUMENTS


FOREIGN PATENT DOCUMENTS

632401v1

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

English language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1400 PTO FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/766,528
				Filing Date	January 29, 2004
				First Named Inventor	SALZWEDEL, Karl
				Art Unit	1648
				Examiner Name	HUMPHREY, Louise Wang Zhiying
Sheet	1	of	2	Attorney Docket Number	1900.0430002/JMC/HCC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	NPL1	Accola, M.A., <i>et al.</i> , "Efficient Particle Production by Minimal Gag Constructs Which Retain the Carboxy-Terminal Domain of Human Immunodeficiency Virus Type 1 Capsid-p2 and a Late Assembly Domain," <i>J. Virol.</i> 74:5395-5402, American Society for Microbiology (2000)	
	NPL2	Adamson, C.S., <i>et al.</i> , "In Vitro Resistance to the Human Immunodeficiency Virus Type 1 Maturation Inhibitor PA-457 (Bevirimat)," <i>J. Virol.</i> , published online, doi:10.1128/JVI.01369-06, 47 pages, American Society for Microbiology (September 2006)	
	NPL3	Kanamoto, T., <i>et al.</i> , "Anti-Human Immunodeficiency Virus Activity of YK-FH312 (a Betulinic Acid Derivative), a Novel Compound Blocking Viral Maturation," <i>Antimicrob. Agents Chemother.</i> 45:1225-1230, American Society for Microbiology (2001)	
	NPL4	Kashiwada, Y., <i>et al.</i> , "3,28-Di-O-(dimethylsuccinyl)-betulin Isomers as Anti-HIV Agents," <i>Bioorg. Med. Chem. Lett.</i> 11:183-185, Pergamon Press (2001)	
	NPL5	Li, F., <i>et al.</i> , "PA-457: A potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 100:13555-13560, National Academy of Sciences (November 2003)	
	NPL6	Li, F., <i>et al.</i> , "Determinants of activity of the HIV-1 maturation inhibitor PA-457," <i>Virology</i> , published online, doi:10.1016/j.virol.2006.07.023, 8 pages, Academic Press (December 2006)	
	NPL7	Liang, C., <i>et al.</i> , "Characterization of a Putative α -Helix across the Capsid-SP1 Boundary That Is Critical for the Multimerization of Human Immunodeficiency Virus Type 1 Gag," <i>J. Virol.</i> 76:11729-11737, American Society for Microbiology (November 2002)	
	NPL8	Morellet, N., <i>et al.</i> , "Helical structure determined by NMR of the HIV-1 (345-392) Gag sequence, surrounding p2: Implications for particle assembly and RNA packaging," <i>Protein Sci.</i> 14:375-386, Cold Spring Harbor Laboratory Press (February 2005)	
	NPL9	Pettit, S.C., <i>et al.</i> , "Replacement of the P1 Amino Acid of Human Immunodeficiency Virus Type 1 Gag Processing Sites Can Inhibit or Enhance the Rate of Cleavage by the Viral Protease," <i>J. Virol.</i> 76:10226-10233, American Society for Microbiology (October 2002)	
	NPL10	Sakalian, M., <i>et al.</i> , "3-O-(3', 3' -Dimethylsuccinyl) Betulinic Acid Inhibits Maturation of the Human Immunodeficiency virus Type 1 Gag Precursor Assembled In Vitro," <i>J. Virol.</i> 80:5716-5722, American Society for Microbiology (June 2006)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Equivalent of Form PTO/SB/08B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/766,528
				Filing Date	January 29, 2004
				First Named Inventor	SALZWEDEL, Karl
				Art Unit	1648
				Examiner Name	HUMPHREY, Louise Wang Zhiying
Sheet	2	of	2	Attorney Docket Number	1900.0430002/JMC/HCC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL11	Schinazi, R.F., <i>et al.</i> , "Mutations in retroviral genes associated with drug resistance," in <i>International Antiviral News</i> 496:95-107, International Medical Press (1996)	
	NPL12	von Schwedler, U.K., <i>et al.</i> , "Functional Surfaces of the Human Immunodeficiency Virus Type 1 Capsid Protein," <i>J. Virol.</i> 77:5439-5450, American Society for Microbiology (May 2003)	
	NPL13	Wieggers, K., <i>et al.</i> , "Sequential Steps in Human Immunodeficiency Virus Particle Maturation Revealed by Alterations of Individual Gag Polyprotein Cleavage Sites," <i>J. Virol.</i> 72:2846-2854, American Society for Microbiology (1998)	
	NPL14	Zhou, J., <i>et al.</i> , "Small-Molecule Inhibition of Human Immunodeficiency Virus Type 1 Replication by Specific Targeting of the Final Step of Virion Maturation," <i>J. Virol.</i> 78:922-929, American Society for Microbiology (January 2004)	
	NPL15	Zhou, J., <i>et al.</i> , "The sequence of the CA-SP1 junction accounts for the differential sensitivity of HIV-1 and SIV to the small molecule maturation inhibitor 3-O-{3',3'-dimethylsuccinyl}-betulinic acid," <i>Retrovirology</i> 1:15, published on-line, doi:10.1186/1742-4690-1-15, 25 pages, BioMed Central (June 2004)	
	NPL16	Zhou, J., <i>et al.</i> , "The Specificity of the Small-Molecule Maturation Inhibitor 3-O-{3',3'-Dimethylsuccinyl}-Betulinic Acid for HIV-1 is Determined by the Sequence of the CA-SP1 Junction of GAG," poster 26, presented at the Fifth HIV DRP Symposium: Antiviral Drug Resistance, Chantilly, VA (November 2004)	
	NPL17	Zhou, J., <i>et al.</i> , "Inhibition of HIV-1 Maturation via Drug Association with the Viral Gag Protein in Immature HIV-1 Particles," <i>J. Biol. Chem.</i> 280:42149-42155, American Society for Biochemistry and Molecular Biology (December 2005)	
	NPL18	Zhou, J., <i>et al.</i> , "HIV-1 Resistance to the Small Molecule Maturation Inhibitor 3-O-{3',3'-dimethylsuccinyl}-betulinic acid is Conferred by a Variety of Single Amino Acid Substitutions at the CA-SP1 Cleavage Site in Gag," <i>J. Virol.</i> , published online, doi:10.1128/JVI.01626-06, 17 pages, American Society for Microbiology (October 2006)	
	NPL19	U.S. National Phase Patent Application No. 11/597,431, Salzwedel <i>et al.</i> , international filing date of May 24, 2005 (NOT PUBLISHED)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.